TYRA
Tyra Biosciences, Inc.
Tyra Biosciences, Inc. insider trading
Tyra Biosciences, Inc. is on this site because an insider bought its stock on the open market in the last 30 days. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
From SEC filings · last 30 days
Recent TYRA insider transactions
The filing store could not be read just now — this page tries again on its next refresh. The filings themselves are on SEC EDGAR.
SEC Form 4 data, Q3 2024 to Q2 2026
TYRA insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 9 insiders traded TYRA on the open market: 8 purchases worth $35.3M and 62 sales worth $19.5M, 30 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 14 sales ($10.6M), by 3 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | −$1M5 sales · 4 on a plan | |
| Q4 2025 | — | −$9.6M9 sales · all on a plan | |
| Q3 2025 | — | — | |
| Q2 2025 | +$15.3M6 buys | −$628.4K5 sales | |
| Q1 2025 | — | −$562.4K8 sales | |
| Q4 2024 | +$20M2 buys | −$7.1M27 sales · 9 on a plan | |
| Q3 2024 | — | −$689.7K8 sales · all on a plan |
- Largest purchase
- +$19.8M of TYRA by RA Capital Healthcare Fund LP (Director · 10% Owner) on Nov 08, 2024.
- Largest sale
- −$5M of TYRA by More Robert J (Director) on Nov 21, 2025, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Kaplan Gilla
Director
−$528.5K
Mar 25, 2026
14,295 sh · $36.97
Bensen Daniel10b5-1
Chief Discovery Officer
−$195.9K
Feb 12, 2026
5,872 sh · $33.37
Bensen Daniel10b5-1
Chief Discovery Officer
−$67K
Feb 12, 2026
2,128 sh · $31.50
Bensen Daniel10b5-1
Chief Discovery Officer
−$198.6K
Jan 12, 2026
6,983 sh · $28.44
Bensen Daniel10b5-1
Chief Discovery Officer
−$29.6K
Jan 12, 2026
1,017 sh · $29.08
More Robert J10b5-1
Director
−$250K
Dec 19, 2025
10,000 sh · $25.00
Bensen Daniel10b5-1
Chief Discovery Officer
−$181.1K
Dec 12, 2025
8,000 sh · $22.64
More Robert J10b5-1
Director
−$5M
Nov 21, 2025
246,871 sh · $20.25
Bensen Daniel10b5-1
Chief Operating Officer
−$815.3K
Nov 19, 2025
49,956 sh · $16.32
Bensen Daniel10b5-1
Chief Operating Officer
−$1.2M
Nov 18, 2025
75,633 sh · $16.07
Bensen Daniel10b5-1
Chief Operating Officer
−$299.2K
Nov 17, 2025
18,572 sh · $16.11
Bensen Daniel10b5-1
Chief Operating Officer
−$25.6K
Nov 17, 2025
1,500 sh · $17.07
Bensen Daniel10b5-1
Chief Operating Officer
−$1.8M
Nov 14, 2025
110,228 sh · $16.02
Bensen Daniel10b5-1
Chief Operating Officer
−$17.8K
Nov 13, 2025
1,111 sh · $16.00
Kaplan Gilla
Director
−$93.6K
Jun 18, 2025
9,568 sh · $9.78
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 25, 2026 | Kaplan GillaDirector | 14,295 | $36.97 | −$528.5K |
| Feb 12, 2026 | Bensen Daniel10b5-1Chief Discovery Officer | 5,872 | $33.37 | −$195.9K |
| Feb 12, 2026 | Bensen Daniel10b5-1Chief Discovery Officer | 2,128 | $31.50 | −$67K |
| Jan 12, 2026 | Bensen Daniel10b5-1Chief Discovery Officer | 6,983 | $28.44 | −$198.6K |
| Jan 12, 2026 | Bensen Daniel10b5-1Chief Discovery Officer | 1,017 | $29.08 | −$29.6K |
| Dec 19, 2025 | More Robert J10b5-1Director | 10,000 | $25.00 | −$250K |
| Dec 12, 2025 | Bensen Daniel10b5-1Chief Discovery Officer | 8,000 | $22.64 | −$181.1K |
| Nov 21, 2025 | More Robert J10b5-1Director | 246,871 | $20.25 | −$5M |
| Nov 19, 2025 | Bensen Daniel10b5-1Chief Operating Officer | 49,956 | $16.32 | −$815.3K |
| Nov 18, 2025 | Bensen Daniel10b5-1Chief Operating Officer | 75,633 | $16.07 | −$1.2M |
| Nov 17, 2025 | Bensen Daniel10b5-1Chief Operating Officer | 18,572 | $16.11 | −$299.2K |
| Nov 17, 2025 | Bensen Daniel10b5-1Chief Operating Officer | 1,500 | $17.07 | −$25.6K |
| Nov 14, 2025 | Bensen Daniel10b5-1Chief Operating Officer | 110,228 | $16.02 | −$1.8M |
| Nov 13, 2025 | Bensen Daniel10b5-1Chief Operating Officer | 1,111 | $16.00 | −$17.8K |
| Jun 18, 2025 | Kaplan GillaDirector | 9,568 | $9.78 | −$93.6K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check TYRA — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
Tyra Biosciences, Inc. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- How much TYRA stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 9 Tyra Biosciences, Inc. insiders made 8 open-market purchases worth $35.3M and 62 sales worth $19.5M. 30 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 14 sales ($10.6M). The largest purchase was RA Capital Healthcare Fund LP buying $19.8M on Nov 08, 2024. The largest sale was More Robert J selling $5M on Nov 21, 2025.
- Where does TYRA insider trading data come from?
- From the Form 4 filings Tyra Biosciences, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.